We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byJames Munford
Modified about 1 year ago
Precise, Real-Time Breathing Tube Monitoring ™ Investor Presentation Venture Forum June 2009
slide 2 © 2009 SonarMed Inc.SonarMed Confidential & Proprietary ™ Why You Should Listen Invest-able Team Chairman = successful experienced entrepreneur President = 20 year medical device veteran CTO = Ph.D. with relevant patent credits VP Regulatory = highly FDA experienced, former respiratory therapist Opinion leading medical advisors Clear & compelling unmet clinical need $5BB+ problem $400MM U.S. market Capital efficient $5.5MM raised, 82% non-dilutive Ready to go Two human studies completed with strong performance 510(k) regulatory path, FDA filing 3Q09 Strategic partner discussions ongoing Launch early 2010
slide 3 © 2009 SonarMed Inc.SonarMed Confidential & Proprietary ™ The Problem Movement Insertion error Tube gets blocked Increased morbidity & mortality Secretions Tube comes out Emergency re-insertion Tube in wrong place Wrong pipe Into the lung
slide 4 © 2009 SonarMed Inc.SonarMed Confidential & Proprietary ™ Significant Unmet Clinical Need 32 question, 74 clinician SonarMed survey shows: Unplanned extubation = high concern (98%) Reintubation = high risk for pneumonia (100%) Ventilator assisted pneumonia (VAP) = high concern (94%) 30% of patients “at risk” for unplanned extubation Valuable to identify location of obstruction (77%) Unplanned Extubation (UE) is the most common ICU endotracheal tube adverse event Incidence rate of ≈ 10% More than doubles ICU stay 60% increase in total hospital stay Nearly triples need for post-ICU chronic care Quintuples risk of contracting pneumonia (40% mortality rate) Is a direct cause of death in some instances UE = $5.25BB issue MM adult ICU intubations x 10% rate of UE x $35,000/incident cost of extended ICU/hospital stay
slide 5 © 2009 SonarMed Inc.SonarMed Confidential & Proprietary ™ The Solution MONITORS: Movement Obstructions Passageway size Reusable Monitor Single Use Adapter PROCESS: Anesthesiologist, ER doc, or EMT places tube SonarMed ™ Adapter replaces standard adapter – sits between tube and ventilator Immediate 24/7 tube monitoring TECHNOLOGY: Exclusive license Issued patents Acoustic signal Echo processing
slide 6 © 2009 SonarMed Inc.SonarMed Confidential & Proprietary ™ U.S. Market Opportunity Adult Hospital SegmentsIntubations/year Adult ICU 1,500,000 Select operating room applications 900,000 Emergency room 300,000 TOTAL 2,700,000 Future Market SegmentsIntubations/year Field/Ambulance* 275,000 NICU/PICU 120,000 Operating room general use15,000,000 TOTAL15,395,000 *Does not include potential military medical applications
slide 7 © 2009 SonarMed Inc.SonarMed Confidential & Proprietary ™ Revenue Model Pricing Single-use $50 (razor blade) – cannot be reprocessed $1000 (razor) Reimbursement Analysis completed (Medicare as model payer) Unique reimbursement not anticipated – sell on cost, quality of care Net avg. hospital savings of $1000/intubated patient is projected Distribution Initial direct sales to flagship accounts Partnership for broad penetration
slide 8 © 2009 SonarMed Inc.SonarMed Confidential & Proprietary ™ Adult Hospital Competition Visual spot checks for position “Teeth checks” (98% use*) Daily chest x-rays (72% use*) Routine and distress suctioning for obstructions “Inferential” technologies Pulse oximetry monitors blood oxygen levels Can be used to infer gross tube issues Used on virtually all ICU patients Capnography monitors exhaled CO 2 levels Can be used to infer gross tube issues (42% use*) *SonarMed clinician survey April 2009 No precise, real-time tube monitoring technology exists in the market today
slide 9 © 2009 SonarMed Inc.SonarMed Confidential & Proprietary ™ Platform Potential Future generation devices Peripheral device reporting to central monitoring station or ventilator Integrated device with capnography and/or pulse oximetry Device targeting additional market segments (neo-peds, pre- hospital, military) R&D opportunities for additional intubation parameters R&D opportunities beyond breathing tube monitoring Tracheostomy tubes Clot formation in venous lines Catheter placement
slide 10 © 2009 SonarMed Inc.SonarMed Confidential & Proprietary ™ Management Dave Wortman, Chairman, experienced technology executive/entrepreneur Andy Cothrel, President, 20 years in medical device development, ops, general management Jeff Mansfield, PhD, Founder and CTO, expertise in biomedical acoustics, 10 years in medical device R&D Laura Lyons, VP Clinical/Quality/Regulatory Affairs, strong background in all aspects of regulatory, quality, and FDA, prior experience as a respiratory therapist SonarMed Team Co-founders and technical advisors George Wodicka, PhD, Professor and Chair, Weldon School of Biomedical Engineering, Purdue University Eduardo Juan, PhD, Professor, Electrical Engineering, University of Puerto Rico Greg Ayers, MD, PhD, Founding member of successful start-ups: InControl, Hemosense, Intraluminal, CryoCor, Alsius Medical Advisory Board Andranik Ovassapian, MD, Professor of Anesthesia and Director of Airway Training Center, University of Chicago; Founding President, Society for Airway Management Elizabeth Behringer, MD, Anesthesiologist/Intensivist, Cedars Sinai Medical Center, and President-elect, Society for Airway Management
slide 11 © 2009 SonarMed Inc.SonarMed Confidential & Proprietary ™ Currently raising $2,500,000 to fund initial launch and outcomes study Spring Mill Venture Partners/Village Ventures $350,000 BioCrossroads/Indiana Seed Fund $500,000 Purdue/Founders Equity $100,000 Indiana 21st Century Fund Grant $1,450,000 NIH (SBIR) Grant $3,100,000 Total financing to date $5,500,000 Financing
slide 12 © 2009 SonarMed Inc.SonarMed Confidential & Proprietary ™ Why Invest in SonarMed? Clear & compelling unmet clinical need Intubation-related adverse events create > $5BB in medical problems Over 15MM intubations/year in the U.S., $400MM market Confirmed with in-depth clinician survey and extensive body of publications Capital efficient $5.5MM raised, 82% non-dilutive ($3.1MM in NIH SBIR grants) Low technology/regulatory risk Exclusive license to issued patents, Freedom to Operate analysis completed Two human studies demonstrate strong product performance 510(k) regulatory path, FDA filing 3Q09 Strategic partner discussions ongoing Medical device suppliers Major distributors Strong team Significant early stage company/medical device experience Distinguished advisors and consultants
BioMedShip Purdue University and Indiana School of Medicine Tim Folta, Ph.D. (Krannert School of Business) George Wodicka, Ph.D. (Weldon School of BME)
(C) Copyright GCT Patented Method This presentation, and the information contained therein, protected by Copyright © 2011 GCT – Global Connectivity.
Building the Best Team that Delivers and that Investors Love TEAMWORK MAKES THE DREAM WORK:
Venture Capital Slide Show Presentation Suggested Format No more than 10 slides (not all slides No more than 10 slides (not all slides shown here will.
1 Bi o medical Designs Provides Smart Catheter Solutions January 2012.
Do You Want to Start a Company? or Lessons from Babs’s Excellent Adventure Babs Soller, PhD Founder, President & Chief Scientific Officer Reflectance Medical.
Finance: Review of Ch What is Finance? 1.2 The Role of the Financial Manager 1.3 Who is the Financial Manager 1.4 Goal of the Firm ? 1.5 Agency Problem.
Sample Template for Pitching Angel Investors (Your Name, Your Phone, Presentation to Big Money Investors/Strategic Partners May.
A powerful, unique (patent pending) website that pulls together everything businesses and projects need for success: Crowdsourcing Crowdfunding Social.
ABC Company John Entrepreneur President and CEO Mississippi Angel Network Start with a “hook”: “I’m sure all of you have experienced the frustration of.
1 The Global Center for Medical Innovation “Accelerating Medical Device Innovation in the Southeast” Southeast Region Technology Transfer Directors Meeting.
[Company Name or Logo] Business Plan Highlights. 3/16/ Agenda Introduction – Overview – The Team – Business Highlights The Opportunity – The Problem.
UTSA CITE Program Boot Camp Feb. 15, 2014 Becky Ariana CEO.
1.Apply online by November 20 – – By answering 19 questions – You can paste from a word doc – Answers limited to 1500.
NHMRC Development Grants David Grayden Biomedical Engineering With some slides borrowed from MDHS.
Life Science Venture Capital 11th Annual NIH SBIR/STTR Conference July 1, 2009 Randy H. Weiss, Ph.D. Partner, Triathlon Medical Ventures.
Students to Start-ups Entrepreneurial Skills Workshop Series The Les Kilpatrick.
BUSINESS STRATEGY AND PLAN 2010 Emerging Energy Solutions 1.
A technology to save lives IV PREV: PREVENTING INFECTIONS Kanika Bansal Founder Medicen Devise Limited Presented to Gabriel 19 th September,
Investor Presentation November Forward Looking Statements This presentation may contain forward-looking statements which are subject to a number.
Overview on financing instruments: Which instruments suit which business idea? ICT 2013 Conference Matthias Frieden, Go Beyond Investing 1www.eig-project.eu.
Entrepreneurship I Class #8 VOSG I Business Plan and Finances.
Cover Life Cycle of Financing 8 South Michigan Suite 400 Chicago, IL p (312) f (312) Linda.
Business Plan Components SectionNumber of Pages Executive Summary1 Company2-3 Management1-2 Product3-5 Market4-7 Competition2-3 Sales and Marketing3 -5.
ABC Company John Entrepreneur President and CEO. 2 Company Overview Provide descriptive but succinct statement about your business.
PureDepth Inc. Ltd Proprietary and Confidential P01 June 2006 Investor Update (PDEP.OB)
MPR Product Development 5 Things Entrepreneurs Need To Know Craig Mauch, Director Product Design November 6, 2013.
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 1 “RDA: better chemotherapy management” Investor Presentation April 2013.
TECHNOLOGY COMMERCIALISATION WORKSHOP Level 1 Business Modeling & Financing for Technology Start-Ups Rashidan Shah Abdul Rahim.
Technology Commercialization Technology Commercialization, 2011 Sanjay Dhole, Technology Programs Coordinator Maricopa SBDC.
“Paying for clinical trials with an SBIR grant” Our experience obtaining millions of dollars through the NIH's Phase II Competing Renewal program Adapted.
1 Company Name (Presenter’s name) Phone # Tag line.
The Medical Director “A Quality Force” Susan L. Goelzer MD, MS, CPE Ralph Waters MD Distinguished Chair Professor of Anesthesiology, Internal Medicine.
Page 1 New Models for Commercialization Federal Partners in Technology Transfer June 18, 2009 A presentation by: Tom Corr Chief Executive Officer Accelerator.
The MBA DIVE Discovery, Innovation, and Ventures Enterprise The mission of the MBA DIVE is to endow students with professional knowledge and skills relevant.
BMES Conference: Student Technology Transfer Brian Mullen, Ph.D.
The Business Plan. Planning as Part of The Business Operations Planning is a process than never ends for a business. It is extremely important in the.
So you want to start a company? A Guide for UMass Faculty, Researchers and Students.
Preparing Your Business Plan. The Components of Successful Entrepreneurial Ventures Business Plan The Entrepreneur Opportunity Resources Organization.
Endotracheal Intubation – Rapid Sequence Intubation.
USING THE ICP EXERCISE TO BETTER UNDERSTAND THE BUSINESS PLAN July 8, 2014 Kelley A. Packalen, PhD Associate Professor of Entrepreneurship, Queen’s School.
Company Due Diligence AIEA March 27, 2008 Sam Thacker Business Finance Solutions
Clarity of purpose Address Large Markets and target Customers who are willing to pay Sharp focus of the product/service (Customer) problem is significant.
Presented by: TBIN, Inc. The Business & Investment Network busnetwk.com (631)
Presentation Tutorial Entrepreneur’s Guide to an Effective Pitch to Investors AmBAR © 2005 All Rights Reserved.
0 Biomedical Engineering Society Annual Meeting - Nashville, TN Presentation to the Biomedical Engineering Society October 2, 2003 Biomedical Engineering.
1 Communicating with Venture Capitalists to Fund Your Research Raising Venture Capita l Michael Jirousek, Ph.D. Senior Advisor, Innovation Support Center.
Story of AntiOp, Inc. (f/k/a Alcomed, Inc.) Daniel Wermeling, Pharm.D. President and CEO Professor of Pharmacy University of Kentucky College of Pharmacy.
Accelerating Your Go-to-Market Strategy By Randy Goldsmith, PhD
© 2017 SlidePlayer.com Inc. All rights reserved.